All - Tozaro

VIDEO – A new approach to designing synthetic affinity ligands for enhanced viral vector analytics and purification

October 16, 2024

Our Head of Cell and Gene Therapy Applications, Abdullah Sufan presented ‘A new approach to designing synthetic affinity ligands for …

Novel synthetic affinity reagents for lentivirus analytics and capture chromatography – Presented at The Bioprocessing Summit 2024

August 30, 2024

By Keli

First presented at The Bioprocessing Summit 2024, this poster introduces a new suite of synthetic affinity reagents targeting VSV-G, a …

MIP Discovery rebrands as Tozaro as it completes transition to supporting cell and gene therapy viral vector analytics and purification

August 5, 2024

By Keli

Bedfordshire, UK, 06 August 2024: MIP Discovery today announced the Company’s rebrand to Tozaro, completing its transition to becoming a …

Developing new tools for rapid quantification of viral vectors – a proof of concept

March 20, 2024

By celf_admin

This is the excerpt display This is the excerpt display This is the excerpt display This is the excerpt display This is the excerpt display This is the excerpt display This is the excerpt display This is the excerpt display

Tozaro closes £7M Series A financing to drive commercialization in cell and gene therapy space

February 19, 2024

By celf_admin

Company’s synthetic affinity reagents are antibody alternatives designed to advance the speed, safety, and efficiency of manufacturing at scale, making …

Tozaro (formally MIP Discovery) secures significant funding to support development of global rapid response diagnostics

February 1, 2023

By celf_admin

Funding received from the Bill & Melinda Gates Foundation for rapid deployment of novel detection reagents to support mass scale …

Fill in the form below to complete your download